VHT

Healthcare ETFs have lagged, but JPMorgan expects a reversal in flows. Eli Lilly and AbbVie may benefit from renewed sector rotation.

Pharmaceuticals are rebounding as U.S. drug pricing clarity emerges. The focus shifts to patent expirations and innovation-driven differentiation.

My clustering stock screener is giving us a much more interesting macro signal than simply energy stocks are strong. The portfolio is not simply long commodities. It's long capital intensity

Big Pharma reached new 52‑week highs on strong Q2 results. Some stocks lag while certain healthcare ETFs offer better income risk/reward.

Hotter-than-expected PCE inflation could keep rates higher. Five defensive ETFs may provide steadier exposure amid persistent price pressures.

A convergence of technology, demographics, and financial innovation is expanding the total addressable market for financial services.

The article appears to discuss investor mindset.

The market is discounting a high‑nominal‑growth, investment‑heavy economy where capital is no longer free but returns remain high enough to compensate.